{"metadata": {"source": "pubchem", "title": "Morphine | C17H19NO3 | CID 5288826 - PubChem", "description": "Morphine | C17H19NO3 | CID 5288826 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5288826", "drug": "Morphine", "cid": 5288826, "char_count": 201355, "word_count": 27013, "doc_id": "doc_53", "num_chunks": 298, "chunk_id": "53::chunk_194", "document_index": 53, "latency_s": 1.802314499989734, "prompt_toks": 53592, "completion_toks": 101, "relevance_score": 0.0011116682}, "content": "Drug: Morphine | cid: 5288826\nSource: pubchem | Source description: Morphine | C17H19NO3 | CID 5288826 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    minimal respiratory depression and stabilizes CBT. All together, we suggest that clonidine promotes autonomic stability and may be a desirable agent to use in infants being treated with therapeutic hypothermia.\n\n\n                    Context: \n                    This excerpt summarizes research findings on the pharmacological effects of clonidine compared to morphine, highlighting its minimal respiratory depression and ability to stabilize core body temperature, suggesting its potential benefit in neonatal therapeutic hypothermia treatments. It is part of a broader review of opioid and alpha-2 adrenergic receptor agonist effects, relevant for understanding safe and effective pain management strategies in infants, and is situated within the document's discussion of drug safety, experimental studies, and clinical implications for vulnerable populations.\n                "}
{"metadata": {"source": "pubchem", "title": "Morphine | C17H19NO3 | CID 5288826 - PubChem", "description": "Morphine | C17H19NO3 | CID 5288826 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5288826", "drug": "Morphine", "cid": 5288826, "char_count": 201355, "word_count": 27013, "doc_id": "doc_53", "num_chunks": 298, "chunk_id": "53::chunk_206", "document_index": 53, "latency_s": 1.5611990000033984, "prompt_toks": 53696, "completion_toks": 89, "relevance_score": 0.000621463}, "content": "Drug: Morphine | cid: 5288826\nSource: pubchem | Source description: Morphine | C17H19NO3 | CID 5288826 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    American Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 2233\n\nOpiate agonists generally should not be used in premature neonates since the drugs reportedly cross the immature blood-brain barrier more readily than they do the mature barrier and thereby produce disproportionate respiratory depression. ... The manufacturers state that commercially available strengths of morphine sulfate extended-release capsules are not appropriate for children and that the contents of the capsules should not be sprinkled onto applesauce for administration to children.\n\nAmerican Society of Health-System Pharmacists 2016; Drug Information 2016. Bethesda, MD. 2016, p. 2234\n\n\n                    Context: \n                    This excerpt discusses neonatal and pediatric considerations for morphine use, highlighting its increased sensitivity and risks in premature and children due to crossing the immature blood-brain barrier, and emphasizing that commercially available extended-release capsules are not suitable for children and should not be sprinkled onto applesauce. It provides important safety guidance relevant to clinicians and formulators, situating within the document's broader focus on chemical safety, dosage, and clinical application of morphine.\n                "}
{"metadata": {"source": "pubchem", "title": "Morphine | C17H19NO3 | CID 5288826 - PubChem", "description": "Morphine | C17H19NO3 | CID 5288826 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/5288826", "drug": "Morphine", "cid": 5288826, "char_count": 201355, "word_count": 27013, "doc_id": "doc_53", "num_chunks": 298, "chunk_id": "53::chunk_167", "document_index": 53, "latency_s": 1.1592934000073, "prompt_toks": 53680, "completion_toks": 86, "relevance_score": 0.00026738262}, "content": "Drug: Morphine | cid: 5288826\nSource: pubchem | Source description: Morphine | C17H19NO3 | CID 5288826 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    enhancement was observed 60 min after haloperidol (0.15 and 0.45 mg/kg) and hyoscine butylbromide co-administration. The addition of haloperidol to morphine significantly increased analgesia in 6-, 8- and 11-month-old rats while in the case of hyoscine butylbromide co-administration this effect was observed only in 11-month-old rats. Haloperidol and hyoscine butylbromide enhanced morphine analgesia. Future studies may explore the repeated administration of these drug combinations in rats and humans.\n\n\n                    Context: \n                    This excerpt details research on how certain adjuvant drugs, haloperidol and hyoscine butylbromide, modulate morphine's analgesic effects in rat models, highlighting age-dependent enhancement of pain relief. It is relevant within the document's section on pharmacological interactions and drug combinations, emphasizing potential for improved analgesic strategies and the need for further studies on repeated use in both animals and humans.\n                "}
